These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24324104)

  • 41. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
    Li J; Sun P; Huang T; He S; Li L; Xue G
    Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel approaches in the treatment of non-small-cell lung cancer.
    Rosell R; Sánchez JM; Tarón M; O'Brate A; Gutiérrez JL; Monzó M; Felip E; Sánchez JJ; Alberola V
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 6):52-60. PubMed ID: 11301850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
    Xu CW; Wang G; Wang WL; Gao WB; Han CJ; Gao JS; Li Y; Wang L; Zhang LY; Zhang YP; Tian YW; Fang JN
    Exp Ther Med; 2015 Mar; 9(3):880-884. PubMed ID: 25667646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
    Schettino C; Bareschino MA; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Genomics; 2008 Jun; 9(4):252-62. PubMed ID: 19452042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.
    Hayashi Y; Kuriyama H; Umezu H; Tanaka J; Yoshimasu T; Furukawa T; Tanaka H; Kagamu H; Gejyo F; Yoshizawa H
    Intern Med; 2009; 48(4):203-8. PubMed ID: 19218769
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Guo N; Zhang W; Zhang B; Li Y; Tang J; Li S; Zhao Y; Zhao Y; Xia H; Yu C
    Mol Clin Oncol; 2015 Sep; 3(5):1123-1128. PubMed ID: 26623063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.
    Huang CL; Kadota K; Liu D; Ueno M; Nakasima N; Ishikawa S; Gotoh M; Misaki N; Chang SS; Yokomise H
    Exp Ther Med; 2010 May; 1(3):445-451. PubMed ID: 22993560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive molecular markers: has the time come for routine use in lung cancer?
    Davies AM; Mack PC; Lara PN; Lau DH; Danenberg K; Gumerlock PH; Gandara DR
    J Natl Compr Canc Netw; 2004 Mar; 2(2):125-31. PubMed ID: 19777702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Role of RRM1 in the Treatment and Prognosis of Advanced Non-small Cell Lung Cancer].
    Tian J; Han S
    Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):381-6. PubMed ID: 26104896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.
    Uramoto H; Akiyama H; Nakajima Y; Kinoshita H; Inoue T; Kurimoto F; Nishimura Y; Saito Y; Sakai H; Kobayashi K
    Case Rep Oncol; 2014 Sep; 7(3):700-10. PubMed ID: 25493083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress in lung cancer: non-oat cell (non-small cell lung cancer).
    Beattie EJ; Raskin NM
    Jpn J Surg; 1987 Sep; 17(5):313-22. PubMed ID: 2828728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer.
    Okuda K; Tatematsu T; Yano M; Nakamae K; Yamada T; Kasugai T; Nishida T; Sano M; Moriyama S; Haneda H; Kawano O; Sakane T; Oda R; Watanabe T; Nakanishi R
    Mol Clin Oncol; 2018 Jul; 9(1):21-29. PubMed ID: 29977535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
    Miao J; Zhang W; Hu X; Chen S; Hu B; Li H
    Thorac Cancer; 2016 Jan; 7(1):44-9. PubMed ID: 26816538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
    Yu Y; Ding S; Liang Y; Zheng Y; Li W; Yang L; Zheng X; Jiang J
    Exp Ther Med; 2014 Jun; 7(6):1578-1582. PubMed ID: 24926347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer.
    Shan F; Liu YL; Wang Q; Shi YL
    Oncol Lett; 2018 Sep; 16(3):3274-3280. PubMed ID: 30127925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the spatial diffusion of methylene blue injected in vivo by bronchoscopy into non-small cell lung carcinoma.
    Vignaud JM; Ménard O; Weinbreck N; Siat J; Borrelly J; Marie B; Martinet N; Martinet Y
    Respiration; 2006; 73(5):658-63. PubMed ID: 16825754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.
    Gao P; Chen H; Zeng T; Wu W; Xu G; Xu C; Zheng B; Zhu Y; Zheng W; Chen C
    Transl Lung Cancer Res; 2020 Oct; 9(5):2157-2160. PubMed ID: 33209635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.
    Schreiner W; Gavrychenkova S; Dudek W; Rieker RJ; Lettmaier S; Fietkau R; Sirbu H
    J Thorac Dis; 2018 May; 10(5):2795-2803. PubMed ID: 29997942
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.
    Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    Onco Targets Ther; 2017; 10():153-163. PubMed ID: 28096683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.
    Allingham-Hawkins D; Lea A; Levine S
    PLoS Curr; 2010 Dec; 2():RRN1202. PubMed ID: 21152077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.